https://european-biotechnology.net/wp-content/uploads/2025/09/Lewy_Body_alphaSynuclein-e1756879718600.jpg
355
631
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-09-03 09:06:55 2025-09-12 10:02:02 Novartis invests US$200min lacklustre Parkinson’s target
https://european-biotechnology.net/wp-content/uploads/2025/09/Cytokinetics_Headquarters-e1756871185507-1030x580-1.jpg
580
1030
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-09-03 03:48:11 2025-09-12 10:02:02 Cytokinetics’ Aficamten with breakthrough Phase III results
https://european-biotechnology.net/wp-content/uploads/2025/09/Polpharma-Biologics-HQ-in-Gdansk-1-2-1-e1756822843167.jpg
451
800
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-09-02 14:29:11 2025-09-12 10:02:02 Polpharma Biologics secures distribution of upcoming biosimilars
https://european-biotechnology.net/wp-content/uploads/2025/09/Genetech_320984427_b8PYYp7YaXx5WBi6WwRXFIg8OupDixUA-e1756802020857.jpg
563
1000
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-09-02 08:37:03 2025-09-12 10:02:02 Genentech inks US$400m IBD deal with OMass Therapeutics
https://european-biotechnology.net/wp-content/uploads/2025/09/Sanofi_1090062434_e0WmVrZU84Vl6P9grrRF5Cmpr0yUupgT-e1756740428940.jpg
563
1000
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-09-01 15:27:51 2025-09-01 15:27:51 Sanofi receives US approval for oral ITP blockbuster
https://european-biotechnology.net/wp-content/uploads/2025/08/matt_cooper_1x-e1756455430543.jpg
270
480
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-08-29 08:19:51 2025-08-29 08:19:51 SitalaBio pays US$670m for Fosun inflammation blocker
https://european-biotechnology.net/wp-content/uploads/2025/08/Lilly-oral-GLP1_1509780785_BFQ4BXGNxP5LkXc8MnrqHsMZUC0tHA45-e1756277416706.jpg
563
1000
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-08-27 06:53:29 2025-08-27 06:53:29 Lilly’s weight loss pill orforglipron meets primary Phase III endpoint
https://european-biotechnology.net/wp-content/uploads/2025/08/Calluna-Pharma_Illustration_how-it-works.jpg-705x1030-1.webp
1030
705
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-08-26 10:47:01 2025-08-26 10:47:01 Calluna Pharma starts efficacy test with unique IPF antibody
https://european-biotechnology.net/wp-content/uploads/2025/08/BioArctic-Receptor-mediated-transport-across-the-blood-brain-barrier-244x300-1-e1756194894210.png
169
300
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-08-26 07:55:22 2025-08-26 07:55:22 Novartis secures US$30m+ licence option from BioArctic
https://european-biotechnology.net/wp-content/uploads/2025/08/Lecanemab-e1756144217541.jpg
394
700
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-08-25 15:50:24 2025-08-25 15:50:24 Alzheimer’s antibody Lecanemab launched in the EU
Scroll to top
Scroll to top
Scroll to top
